INCHEON, South Korea, September 16, 2020 / PRNewswire / – Samsung Biologics (207940.KS) has entered into a service agreement with Panolos Bioscience to develop PB101, an Fc fusion protein for treating solid tumors.
As part of this agreement, Samsung Biologics will provide a full range of its development services, from cell line development, process development to manufacturing of non-clinical and clinical materials.
According to Panolos, PB101 should more effectively suppress tumor angiogenesis by targeting VEGF-A and PlGF simultaneously, overcoming the limitations of existing treatments. By leveraging Samsung Biologics’ strong capabilities and expertise in the development of complex proteins, Panolos intends to obtain successful IND approval for validation to further establish the substance as a new platform. form known as αARTTM(abased on anti-angiogenesis Artifact Relectronic targeting Tri-specific) to treat various diseases related to VEGF.
Dr. Hyeseong Lim“Said the CEO of Panolos Bioscience,” PB101 itself is a promising candidate for the treatment of solid tumors and VEGF-related diseases. Moreover, it is also a platform technology which has demonstrated its versatility as a basis on which multi-specific biologics can be used. Through close collaborative efforts, Panolos will strive to provide quality biopharmaceuticals to meet unmet global medical needs. “
“We are extremely proud to partner with Panolos to bring the PB101 closer to the market,” said Dr. Tae Han Kim, CEO of Samsung Biologics. “By providing faster, better development services and helping our customers focus on discovery, we will continue to support biotech companies in their efforts to help patients in need around the world.
About Samsung Biologics Co., Ltd.
Samsung Biologics (KRX: 207940.KS) is a fully integrated CDMO offering state-of-the-art development, manufacturing and laboratory testing services. With proven regulatory approvals, the highest capacity at a single site, and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is uniquely capable of supporting the development and manufacture of biologics every step of the way while respecting the evolving needs of biopharmaceutical companies around the world. For more information, visit www.samsungbiologics.com.
Claire Kim [email protected]
SOURCE Samsung Biologics